The Significance Of p53 And p170 Expression In Hepatocellular Carcinoma
Ragaey R. Fahmy MD, Sami A. Darwish Ph.D., Samia A. Youssef, Ph.D. Magdy Saber MD, and Eman S. Omar. M.Sc.
Departments of pathology, Benha faculty of medicine
Benha University and oncology medicine, National Cacer Institute.
a b s t r a c t
Expression of p53 and p170 was investigated in 27 hepatocellular carcinoma (HCC) by means of immunohistochemistry. P53 expression was demonstrated in 10 out of 27 HCC (37%) with incidence increasing in proportion to the histological grading of malignancy, thus 7.7% of well differentiated, 54.5% of moderately differentiated and 100% of poorly differentiated lesions were positive.
P27 expression in non-metastasizing PTC was lower than normal thyroid tissue (P≤ 0.01) and higher than metastasizing PTC (P≤ 0.01), p53 immunoreactivity was present, faint (grade 1) in 2 cases (11%) and moderate (grade 2) in one case ( 5.5%) of non-metastasizing PTC, while 15 (83.5%) cases on non-metastasizing PTCs and all of metastasizing PTCs and normal thyroid tissue had no immunoreactivity for p53. There was no statistically significanct difference among all groups of immunoreactivity for p53. Expression of Bax in patients with PTC was more than normal thyroid tissue ( P≤ 0.01). However, non-metastasizing and metastasizing PTC was similar. The results indicate that the metastasizing PTC showed significantly low CD44 expression than the non-metastasizing PTC (p ≤ 0.05), also the metastasizing and non-metastasizing PTC showed significantly less CD44 expression than the normal tissue (p≤ 0.05).
The immunohistochemical evaluation of p27 and CD44 expression in patients with PTC may be useful to predict for metastasis risk of the PTC to regional lymph nodes.
Research in Benha M.J. 14 (1)(1997) 427–438.